Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Magnitude of HDL cholesterol variation after high-dose atorvastatin is genetically determined at the LDL receptor locus in patients with homozygous familial hypercholesterolemia.
Sposito AC, Gonbert S, Bruckert E, Atassi M, Beucler I, Amsellem S, Khallouf O, Benlian P, Turpin G. Sposito AC, et al. Among authors: gonbert s. Arterioscler Thromb Vasc Biol. 2003 Nov 1;23(11):2078-82. doi: 10.1161/01.ATV.0000097768.51278.91. Epub 2003 Sep 25. Arterioscler Thromb Vasc Biol. 2003. PMID: 14512370 Clinical Trial.
SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia.
Gallo A, Charriere S, Vimont A, Chapman MJ, Angoulvant D, Boccara F, Cariou B, Carreau V, Carrié A, Bruckert E, Béliard S; French REgistry of Familial hypERCHOLesterolemia (REFERCHOL) investigators. Gallo A, et al. Atherosclerosis. 2020 Aug;306:41-49. doi: 10.1016/j.atherosclerosis.2020.06.011. Epub 2020 Jul 6. Atherosclerosis. 2020. PMID: 32688103 Free article.
The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia.
Gallo A, Pérez de Isla L, Charrière S, Vimont A, Alonso R, Muñiz-Grijalvo O, Díaz-Díaz JL, Zambón D, Moulin P, Bruckert E, Mata P, Béliard S; REFERCHOL and SAFEHEART Investigators. Gallo A, et al. JACC Cardiovasc Imaging. 2021 Dec;14(12):2414-2424. doi: 10.1016/j.jcmg.2021.06.011. Epub 2021 Jul 14. JACC Cardiovasc Imaging. 2021. PMID: 34274263 Free article.
Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT).
Le Floch JP, Lévy M, Mosnier-Pudar H, Nobels F, Laroche S, Gonbert S, Eschwege E, Fontaine P; Assessment of Detemir Administration in Progressive Treat-to-Target Trial (ADAPT) Study Group. Le Floch JP, et al. Among authors: gonbert s. Diabetes Care. 2009 Jan;32(1):32-7. doi: 10.2337/dc08-0332. Epub 2008 Oct 22. Diabetes Care. 2009. PMID: 18945928 Free PMC article. Clinical Trial.